Valneva's Chikungunya Vaccine Faces UK Restrictions for Over-60s

Edgen Stock

·Feb 13 2026, 16:58

Share to

Share to

Copy link

Key Takeaways

The United Kingdom's Commission on Human Medicines (CHM) has imposed significant usage restrictions on Valneva's chikungunya vaccine, IXCHIQ®, following a review of its benefits and risks. The new guidelines are expected to limit the vaccine's market potential and negatively impact investor sentiment.

UK Restriction: The CHM has restricted the use of IXCHIQ® for individuals over 60 years of age and those with certain pre-existing health conditions.
Market Shrinks: These limitations reduce the addressable market for the single-dose vaccine, particularly among older travelers who represent a key demographic for travel-related immunizations.
Stock Pressure: The news is expected to place downward pressure on Valneva's stock (VALN) as analysts reassess the commercial outlook for one of its key products.

UK Restricts IXCHIQ Vaccine for Individuals Over 60

Valneva SE confirmed on February 13, 2026, that the United Kingdom's Commission on Human Medicines (CHM) has narrowed the recommended use of its chikungunya vaccine, IXCHIQ®. Following a review of the vaccine's benefit-risk profile, the CHM will now restrict its use in individuals over 60 years old. The updated guidelines also advise against its use in people with certain specified health conditions and include new recommendations on the timing of vaccination before travel.

Commercial Outlook Dims for Key Vaccine

The restrictions directly challenge the commercial prospects for IXCHIQ® in the UK, a notable travel market. By excluding the over-60 demographic, Valneva loses access to a significant segment of potential customers for travel vaccines. This development will force a downward revision of sales forecasts for the single-dose product. The negative news is anticipated to weigh on Valneva's stock (VALN) as investors re-evaluate the vaccine's long-term revenue potential and its contribution to the company's growth.